There is possible good news is the study of Alzheimer’s disease. Researchers from Lund University, together with the Roche pharmaceutical company, have used a method to develop a new blood marker capable of detecting whether or not a person has Alzheimer’s disease. If the method is approved for clinical use, the researchers hope eventually to see it used as a diagnostic tool in primary healthcare. This autumn, they will start a trial in primary healthcare to test the technique.
Currently, a major support in the diagnostics of Alzheimer’s disease is the identification of abnormal accumulation of the substance beta-amyloid, which can be detected either in a spinal fluid sample or through brain imaging using a PET scanner. Continue reading
We are eating less; moving more and hopefully living longer, but it is imperative that we have a fully functioning brain or our work will be in vain.
A simple and inexpensive word recall test accurately predicted whether people had elevated brain levels of beta-amyloid. Scientists hope this non-invasive stress test that puts pressure on memory–similar to how an exercise stress test checks cardiovascular health–could help identify subtle signs of cognitive impairment that may have previously been missed by standard memory tests.
An NIA-supported team of researchers led by Dr. David Loewenstein of the Center for Cognitive Neurosciences and Aging and the University of Miami Miller School of Medicine developed the Loewenstein-Acevedo Scales for Semantic Interference and Learning (LASSI-L) test. Their preliminary findings were published in the September 4, 2018 issue of Neurology.